Significance of the TMPRSS2:ERG gene fusion in prostate cancer

被引:84
作者
Wang, Zhu [1 ,2 ]
Wang, Yuliang [3 ]
Zhang, Jianwen [1 ,2 ]
Hu, Qiyi [1 ,2 ]
Zhi, Fan [1 ,2 ]
Zhang, Shengping [1 ,2 ]
Zhang, Ying [1 ,2 ]
Liang, Hui [1 ,2 ]
机构
[1] Southern Med Univ, Dept Urol, Peoples Hosp Longhua New Dist Shenzhen, 38 Jianshe Rd,Longhua St, Shenzhen 518109, Guangdong, Peoples R China
[2] Southern Med Univ, Affiliated Shenzhen Longhua Hosp, 38 Jianshe Rd,Longhua St, Shenzhen 518109, Guangdong, Peoples R China
[3] Peking Univ, Dept Urol, Peoples Hosp, Beijing 100044, Peoples R China
关键词
prostate cancer; transmembrane protease serine 2; v-ets erythroblastosis virus E26 oncogene homolog; fusion gene; bioinformatics; ERG EXPRESSION; IDENTIFICATION; STATISTICS;
D O I
10.3892/mmr.2017.7281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion is common in prostate cancer, while its functional role is not fully understood. The present study aimed to investigate the significance of the TMPRSS2:ERG gene fusion in human prostate cancers using bioinformatics tools. Comprehensive alteration analysis of TMPRSS2 and ERG in 148 different human cancer studies was performed by cBioPortal, and the mRNA expression level of the ERG gene was evaluated using Oncomine analysis. Furthermore, lentiviral short hairpin (sh)RNA-mediated knockdown of TMPRSS2:ERG was performed to study the impact of ERG silencing on cell proliferation and cell cycle distribution in prostate cancer cells. The results demonstrated that the TMPRSS2 and ERG genes were mostly altered in prostate cancer, and the most frequent alteration was gene fusion. Oncomine analysis demonstrated that the ERG gene was significantly upregulated in prostate clinical samples compared with the normal prostate gland in four independent datasets, and a positive association was observed between potassium inwardly-rectifying channel subfamily J member 15, down syndrome critical region gene 4, potassium inwardly-rectifying channel subfamily J member 6 and ERG gene expression. There were 272 mutations of the ERG gene identified in the cBioPortal database; among the mutations, 2 missense mutations (R367C and P401H) were regarded as functional mutations (functional impact score > 1.938). Furthermore, the present study successfully knocked down ERG gene expression through a lentiviral-mediated gene silencing approach in VCaP prostate cancer cells. The ERG mRNA and protein expression levels were both suppressed significantly, and a cell-cycle arrest at G(0)/G(1) phase was observed after ERG gene silencing. In conclusion, these bioinformatics analyses provide novel insights for TMPRSS2:ERG fusion gene study in prostate cancer. Target inhibition of ERG expression could significantly cause cell growth arrest in prostate cancer cells, which could be a potentially valuable target for prostate cancer treatment. However, the precise mechanism of these results remains unclear; therefore, further studies are required.
引用
收藏
页码:5450 / 5458
页数:9
相关论文
共 50 条
[41]   Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer [J].
Shao, Longjiang ;
Kahraman, Nermin ;
Yan, Ge ;
Wang, Jianghua ;
Ozpolat, Bulent ;
Ittmann, Michael .
PROSTATE, 2020, 80 (01) :65-73
[42]   Detection of tmprss2-erg and tmprss2-egr1 gene fusion in prostate cancer from a Chinese population [J].
Xu, Changqing ;
Luo, Jindan ;
Wang, Mengmeng ;
Wang, Yin ;
Chen, Zhaojing ;
Cao, Yifei ;
Hong, Yu ;
Xu, Xianrong ;
Yang, Jun .
EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2020, 21 (01)
[43]   Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer [J].
Kissick, Haydn Thomas ;
Sanda, Martin George ;
Dunn, Laura Kathleen ;
Arredouani, Mohamed Simo .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (12) :1831-1840
[44]   TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis [J].
Rostad, Kari ;
Hellwinkel, Olaf J. C. ;
Haukaas, Svein A. ;
Halvorsen, Ole J. ;
Oyan, Anne M. ;
Haese, Alexander ;
Budaus, Lars ;
Albrecht, Heiko ;
Akslen, Lars A. ;
Schlomm, Thorsten ;
Kalland, Karl-Henning .
APMIS, 2009, 117 (08) :575-582
[45]   Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors [J].
Geybels, Milan S. ;
Alumkal, Joshi J. ;
Luedeke, Manuel ;
Rinckleb, Antje ;
Zhao, Shanshan ;
Shui, Irene M. ;
Bibikova, Marina ;
Klotzle, Brandy ;
van den Brandt, Piet A. ;
Ostrander, Elaine A. ;
Fan, Jian-Bing ;
Feng, Ziding ;
Maier, Christiane ;
Stanford, Janet L. .
CLINICAL EPIGENETICS, 2015, 7
[46]   Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes [J].
Penney, Kathryn L. ;
Pettersson, Andreas ;
Shui, Irene M. ;
Graff, Rebecca E. ;
Kraft, Peter ;
Lis, Rosina T. ;
Sesso, Howard D. ;
Loda, Massimo ;
Mucci, Lorelei A. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (05) :745-749
[47]   Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion [J].
Guo, Charles C. ;
Zuo, Geyan ;
Cao, Dongdong ;
Troncoso, Patricia ;
Czerniak, Bogdan A. .
MODERN PATHOLOGY, 2009, 22 (07) :866-871
[48]   TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer [J].
Adra, Nabil ;
Cheng, Liang ;
Hanna, Nasser H. ;
Durm, Greg .
CLINICAL GENITOURINARY CANCER, 2017, 15 (03) :E489-E491
[49]   Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy [J].
Merdan, Selin ;
Tomlins, Scott A. ;
Barnett, Christine L. ;
Morgan, Todd M. ;
Montie, James E. ;
Wei, John T. ;
Denton, Brian T. .
CANCER, 2015, 121 (22) :4071-4079
[50]   Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer [J].
Kluth, Martina ;
Volta, Heinke ;
Hussein, Mohammad ;
Taskin, Billurvan ;
Frogh, Sohall ;
Moeller-Koop, Christina ;
Buescheck, Franziska ;
Jacobsen, Frank ;
Tsourlakis, Maria Christina ;
Luebke, Andreas M. ;
Hinsch, Andrea ;
Clauditz, Till ;
Graefen, Markus ;
Heinzer, Hans ;
Huland, Hartwig ;
Minner, Sarah ;
Sauter, Guido ;
Wilczak, Waldemar ;
Schlomm, Thorsten ;
Simon, Ronald .
CANCER MANAGEMENT AND RESEARCH, 2018, 10 :5909-5917